KDR and neoplasm: In HNSCC, preclinical studies in murine models have demonstrated that treatment with sunitinib, a multi-tyrosine kinase inhibitor that targets VEGFR, leads to a reduction of tumor microvessel density with subsequent tumor regression and oxygenation [168].